Table 2.
Novel compounds in development for the treatment of panic disorder (PD)
| Novel drug | Dosage (mg/day) | Experimental method | Study design (type of study, sample size, duration of study) | Mechanism of action | Major finding | Reference (trial) |
|---|---|---|---|---|---|---|
| Eglumegad or LY354740 | 200, twice daily | Single breath of 35% CO2/65% O2 mixture | Double-blind, randomized placebo controlled (4 wk, 30 PD patients) | mGluR2/3 | LY354740>placebo | Schoepp et al., 200365) |
| Eglumegad or LY354740 | 100 or 200, paroxetine 60 | - | Double-blind, randomized placebo controlled (9 wk, 37 PD patients) | mGluR2/3 | LY354740=paroxetine=placebo | Bergink et al., 200566) |
| LY544344 | 80 | Intravenous injection of 50 μg CCK-4 | Double-blind, randomized, placebo controlled, cross-over (1 wk, 12 healthy human) | mGluR2/3 | LY544344>placebo | Kellner et al., 200568) |
| Levetiracetam | 250, twice daily | - | Non-controlled (12 wk, 18 PD patients) | Synaptic vesicle protein 2A | Effective | Papp, 200672) |
mGluR2/3, type II metabotropic glutamate receptors; CCK-4, cholecystokinin tetrapeptide; =, equal efficiency; >, superior than.